EUCTR2016-003866-14-SK进行中（未招募）1 期
A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 17,476
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1.Evidence of a personally signed and dated ICD indicating that the subject has been informed of all pertinent aspects of the study.
- •2.Willing and able to comply with scheduled visits, vaccination plan, and other study procedures.
- •3.50 Years or older at enrollment.
- •4.Subjects with an increased risk of future contact with healthcare systems by virtue of:
- •At least 1 inpatient hospitalization =2 nights’ duration in the previous 12 months; or
- •At least 2 emergency room visits in the previous 12 months; or
- •At least 10 outpatient visits (primary and/or secondary care visits; defined as an in-person visit to the office/clinic of a prescribing healthcare provider for the purposes of the diagnosis, treatment, or ongoing management of a medical condition, excluding pharmacy and mental health visits) in the previous 12 months; or
- •Residence in a skilled nursing facility (a residential institution that provides professional nursing care and rehabilitation services, usually following discharge from the hospital); or
- •Residence in a nursing home (a residential institution that provides assistance with activities of daily living); or
- •Inpatient hospitalization =2 nights’ duration scheduled =37 days after randomization.
- •Or subjects who have received systemic (ie, oral or injected) antibiotics for a minimum of 48 hours at any time in the previous 12 weeks.
- •5.Ability to be contacted by telephone during study participation.
- •6.Negative urine pregnancy test for female subjects of childbearing potential.
- •Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:
- •a.Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state;
- •b.Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- •c.Have medically confirmed ovarian failure.
- •All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12000
排除标准
- •Subjects with any of the following characteristics/conditions will not be included in the study:
- •1.Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- •2.Participation in other studies involving investigational drug(s)/vaccine(s) within 28 days prior to study entry until Visit 5 (1 month after the third vaccination).
- •3.Previous administration of an investigational C difficile vaccine or C difficile mAb therapy.
- •4.Prior episode of CDI, confirmed by either laboratory test or diagnosis of pseudomembranous colitis at colonoscopy, at surgery, or histopathologically.
- •5.Receipt of blood products or immunoglobulins within 6 months before enrollment.
- •6.Subjects who may be unable to respond to vaccination because of:
- •Metastatic malignancy; or
- •End-stage renal disease (glomerular filtration rate <15 mL/min/1.73 m2 or on dialysis); or
- •Any serious medical disorder that in the investigator’s opinion is likely to be fatal within the next 12 months; or
- •Congenital or acquired immunodeficiency; or
- •Receipt of systemic corticosteroids (=20 mg/day of prednisone or equivalent) for =14 days within 28 days of enrollment; or
- •Receipt of chronic systemic treatment with other known immunosuppressant medications, or radiotherapy, within 6 months of enrollment.
- •7.Known infection with human immunodeficiency virus (HIV).
- •8.Any bleeding disorder or anticoagulant therapy that would contraindicate intramuscular injection.
- •9.Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.
- •10.Prior small- or large-bowel resection (does not include appendectomy).
- •11.Any condition or treatment resulting in frequent diarrhea (=3 loose stools per day more than once per month), as reported by the subject.
- •12.Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavioral or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •13.Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) and are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol from the signing of the informed consent until at least 28 days after the last dose of investigational product.
研究者
相似试验
招募中
1 期
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).CTIS2023-506669-70-00Alexion Pharmaceuticals Inc.982
进行中（未招募）
1 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCCResectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001974-76-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Recurrent, Platinum-Sensitive Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005099-21-NOMersana Therapeutics, Inc.581
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to study the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageAcute Migraine (with or without aura)MedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005246-15-PLPfizer Inc.640
进行中（未招募）
1 期
Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormalityMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2021-000761-33-PLKronos Bio, Inc.180